FDA committee backs Centocor psoriasis drug

J&J's Centocor won a key vote by an FDA expert committee backing the approval of ustekinumab for moderate to severe psoriasis. But the experts also want to make sure that the developer continues studies exploring possible links between the drug and a heightened risk of cancer and infections. The drug works by targeting the patient's immune system.

"This drug has the potential to be so helpful for patients, and I think it raises an ethical question if we keep it from them," said panel member Lynn A. Drake.

- check out this release
- read the story from Dow Jones

Suggested Articles

In this week's EuroBiotech Report, Roche's risdiplam clears another phase 3 SMA trial, Merck KGaA spinout raises cash and Korean VCs back PDC*line.

In our EuroBiotech roundup this week, a liver disease biotech raises €11 million, Autolus offers stock and Abivax plans midphase trial. 

Merck KGaA spinout iOnctura has raised a €15 million series A round to support an early-phase solid tumor trial of a PI3Kδ inhibitor.